What does Solu Therapeutics do?
Solu Therapeutics is a biotechnology company based in Boston, MA that is pioneering treatments aimed at eliminating disease-driving cells. Utilizing its proprietary CyTAC and TicTAC platforms, the company is focused on advancing therapies in cancer, immunology, and other therapeutic areas, with its lead candidate STX-0712 in Phase 1 clinical development.
How much did they raise?
The company raised $41M in a Series A round that featured robust backing from both new and existing investors. New participants included Eli Lilly and Company, Biovision Ventures, Pappas Capital, Hengdian Group Capital, and The Leukemia & Lymphoma Society Therapy Acceleration Program, while returning investors such as Longwood Fund, DCVC Bio, Santé Ventures, Astellas Venture Management, and Alexandria Venture Investments continued their support.
What are their plans for the money?
With the new funds, Solu Therapeutics plans to complete dose escalation of its lead CCR2-CyTAC program STX-0712 for the treatment of CMML, expand its pipeline with new development candidates including a first‐in‐class mast cell depletor for immunological diseases, and launch additional discovery programs aimed at targeting pathogenic cells. These initiatives are expected to accelerate its overall mission to bring innovative therapies to patients in need.
What have they achieved so far?
The company has already demonstrated progress with its lead product candidate, STX-0712, which is now in Phase 1 clinical development. This advancement, underpinned by its unique therapeutic platforms, underscores its commitment to revolutionizing treatment options for complex diseases.
